U.K. readies dementia R&D investment fund

Nick Paul Taylor

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound R&D .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS